dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Castiglione, M. | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Castiglione, M. | en |
dc.date.accessioned | 2018-06-22T09:54:29Z | |
dc.date.available | 2018-06-22T09:54:29Z | |
dc.date.issued | 2008 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42373 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Bleomycin | en |
dc.subject | Chlormethine | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Dacarbazine | en |
dc.subject | Dactinomycin | en |
dc.subject | Doxorubicin | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Procarbazine | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Female | en |
dc.subject | Mammography | en |
dc.subject | Carboplatin | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm staging | en |
dc.subject | Priority journal | en |
dc.subject | Ondansetron | en |
dc.subject | Cancer staging | en |
dc.subject | Drug exposure | en |
dc.subject | Neoplastic | en |
dc.subject | Pregnancy complications | en |
dc.subject | Pregnant woman | en |
dc.subject | Prenatal exposure | en |
dc.subject | Cancer diagnosis | en |
dc.subject | Pregnancy | en |
dc.subject | Busulfan | en |
dc.subject | Melphalan | en |
dc.subject | Mercaptopurine | en |
dc.subject | Pregnancy complication | en |
dc.subject | Bisphosphonic acid derivative | en |
dc.subject | Melanoma | en |
dc.subject | Uterine cervix cancer | en |
dc.subject | Risk assessment | en |
dc.subject | Incidence | en |
dc.subject | Follow-up studies | en |
dc.subject | Cancer incidence | en |
dc.subject | Pathology | en |
dc.subject | Cancer therapy | en |
dc.subject | Nuclear magnetic resonance imaging | en |
dc.subject | Thorax radiography | en |
dc.subject | Ifosfamide | en |
dc.subject | Therapy delay | en |
dc.subject | Practice guideline | en |
dc.subject | Physical examination | en |
dc.subject | Medical society | en |
dc.subject | Reproductive toxicity | en |
dc.subject | Antiinflammatory agent | en |
dc.subject | Cytokine | en |
dc.subject | Lymphoma | en |
dc.subject | Chlorambucil | en |
dc.subject | Treatment indication | en |
dc.subject | Paracetamol | en |
dc.subject | Metoclopramide | en |
dc.subject | Aspiration biopsy | en |
dc.subject | Thiotepa | en |
dc.subject | Analgesic agent | en |
dc.subject | Echography | en |
dc.subject | Cryopreservation | en |
dc.subject | Female fertility | en |
dc.subject | Acute leukemia | en |
dc.subject | Pregnancy termination | en |
dc.subject | Opiate | en |
dc.subject | Fertility | en |
dc.subject | Radiation exposure | en |
dc.subject | Radiation hazard | en |
dc.title | Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdn118 | |
dc.description.volume | 19 | |
dc.description.issue | SUPPL. 2 | en |
dc.description.startingpage | ii108 | |
dc.description.endingpage | ii109 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |